GlaxoSmithKline (GSK) Gets a Hold from Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline today and set a price target of £19.00.
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Papadakis is a 4-star analyst with an average return of 3.5% and a 51.16% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Roche Holding AG, GlaxoSmithKline, and AstraZeneca.
In addition to Deutsche Bank , GlaxoSmithKline also received a Hold from TipRanks – OpenAI’s OpenAI Health Care GB in a report issued today. However, on the same day, Barclays maintained a Sell rating on GlaxoSmithKline (LSE: GSK).
Based on GlaxoSmithKline’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p8.62 billion and a net profit of p636 million. In comparison, last year the company earned a revenue of p8.12 billion and had a net profit of p414 million
Based on the recent corporate insider activity of 327 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GSK in relation to earlier this year.
Read More on GB:GSK:
Disclaimer & DisclosureReport an Issue
- GSK Expands Share Buyback, Lifts Treasury Holding to 6.25% of Voting Rights
- GSK directors boost holdings with coordinated share purchases
- GSK Adds 96,525 Shares to LSE Listing Under Employee Share Plans
- GSK announces risvutatug rezetecan received ODD from Japan’s Ministry of Health
- GSK expands share buyback, lifts treasury holdings and updates voting rights
